High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure.Clin Respir J 2018; 12(6):2046-2056CR
Abstract
INTRODUCTION
Severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a significant event that results in substantial mortality.
OBJECTIVES
We evaluated the effectiveness of the high flow nasal cannulae (HFNC) therapy in severe AECOPD with moderate hypercapnic acute respiratory failure (ARF) compared to non-invasive ventilation (NIV).
METHODS
The prospective observational trial was performed to compare the effectiveness between the HFNC and NIV in severe AECOPD with moderate hypercapnic ARF. The end point was the intubation rate and 30-day mortality.
RESULTS
Ninety-two AECOPD patients enrolled during study periods. The median age was 73 (66.5-79) years, and 57 patients (64.8%) were male. Forty-four patients were assigned to HFNC, and 44 patients were assigned to NIV. The intubation rate at day 30 was 25.0% in the HFNC group and 27.3% in the NIV group (P = .857), and the 30-day mortality was 15.9% in the HFNC group and 18.2% in the NIV group (P = .845). The pH (7.38 ± 0.59 vs 7.36 ± 0.10, P = .295), PaO2 (82.2 ± 24.9 vs 81.6 ± 21.7 mm Hg, P = .899) and PaCO2 (46.8 ± 15.2 vs 51.7 ± 17.2 mm Hg, P = .160) after 6 hours and the pH (7.39 ± 0.07 vs 7.39 ± 0.08, P = .743), PaO2 (84.3 ± 18.5 vs 84.7 ± 23.2 mm Hg, P = .934) and PaCO2 (47.0 ± 16.0 vs 49.6 ± 13.7 mm Hg, P = .422) after 24 hours were not significantly different.
CONCLUSION
There was no difference of the 30-day mortality and intubation rate between HFNC and NIV groups.
MeSH
Pub Type(s)
Journal Article
Observational Study
Language
eng
PubMed ID
29392846
Citation
Lee, Myoung Kyu, et al. "High Flow Nasal Cannulae Oxygen Therapy in Acute-moderate Hypercapnic Respiratory Failure." The Clinical Respiratory Journal, vol. 12, no. 6, 2018, pp. 2046-2056.
Lee MK, Choi J, Park B, et al. High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure. Clin Respir J. 2018;12(6):2046-2056.
Lee, M. K., Choi, J., Park, B., Kim, B., Lee, S. J., Kim, S. H., ... Lee, W. Y. (2018). High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure. The Clinical Respiratory Journal, 12(6), pp. 2046-2056. doi:10.1111/crj.12772.
Lee MK, et al. High Flow Nasal Cannulae Oxygen Therapy in Acute-moderate Hypercapnic Respiratory Failure. Clin Respir J. 2018;12(6):2046-2056. PubMed PMID: 29392846.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure.
AU - Lee,Myoung Kyu,
AU - Choi,Jaehwa,
AU - Park,Bonil,
AU - Kim,Bumjoon,
AU - Lee,Seok Jeong,
AU - Kim,Sang-Ha,
AU - Yong,Suk Joong,
AU - Choi,Eun Hee,
AU - Lee,Won-Yeon,
Y1 - 2018/03/05/
PY - 2016/11/20/received
PY - 2017/08/28/revised
PY - 2018/01/26/accepted
PY - 2018/2/3/pubmed
PY - 2018/11/27/medline
PY - 2018/2/3/entrez
KW - chronic obstructive pulmonary disease
KW - exacerbation
KW - intubation
KW - mortality
KW - pneumonia
KW - respiratory failure
SP - 2046
EP - 2056
JF - The clinical respiratory journal
JO - Clin Respir J
VL - 12
IS - 6
N2 - INTRODUCTION: Severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a significant event that results in substantial mortality. OBJECTIVES: We evaluated the effectiveness of the high flow nasal cannulae (HFNC) therapy in severe AECOPD with moderate hypercapnic acute respiratory failure (ARF) compared to non-invasive ventilation (NIV). METHODS: The prospective observational trial was performed to compare the effectiveness between the HFNC and NIV in severe AECOPD with moderate hypercapnic ARF. The end point was the intubation rate and 30-day mortality. RESULTS: Ninety-two AECOPD patients enrolled during study periods. The median age was 73 (66.5-79) years, and 57 patients (64.8%) were male. Forty-four patients were assigned to HFNC, and 44 patients were assigned to NIV. The intubation rate at day 30 was 25.0% in the HFNC group and 27.3% in the NIV group (P = .857), and the 30-day mortality was 15.9% in the HFNC group and 18.2% in the NIV group (P = .845). The pH (7.38 ± 0.59 vs 7.36 ± 0.10, P = .295), PaO2 (82.2 ± 24.9 vs 81.6 ± 21.7 mm Hg, P = .899) and PaCO2 (46.8 ± 15.2 vs 51.7 ± 17.2 mm Hg, P = .160) after 6 hours and the pH (7.39 ± 0.07 vs 7.39 ± 0.08, P = .743), PaO2 (84.3 ± 18.5 vs 84.7 ± 23.2 mm Hg, P = .934) and PaCO2 (47.0 ± 16.0 vs 49.6 ± 13.7 mm Hg, P = .422) after 24 hours were not significantly different. CONCLUSION: There was no difference of the 30-day mortality and intubation rate between HFNC and NIV groups.
SN - 1752-699X
UR - https://www.unboundmedicine.com/medline/citation/29392846/full_citation
L2 - https://doi.org/10.1111/crj.12772
DB - PRIME
DP - Unbound Medicine
ER -
